Form 4: Zoetis EVP Lagano Receives Equity Grants

Zoetis Inc. Executive Vice President Roxanne Lagano reported new grants of restricted stock units and stock options as part of her compensation.

Summary

• Roxanne Lagano, Executive Vice President of Zoetis Inc. (ZTS), reported changes in beneficial ownership through the grant of equity awards.
• A total of 3,664 Restricted Stock Units (RSUs) were granted on February 18, 2026, with each RSU representing a contingent right to receive one share of Zoetis Inc. common stock.
• These 3,664 RSUs will vest in one-third increments on the first, second, and third anniversaries of the grant date, subject to continued service.
• Additional RSUs of 2,250.4257 units were reported, with vesting scheduled on the first, second, and third anniversaries of February 19, 2025.
• Another 545 RSUs were reported, with vesting scheduled on the first, second, and third anniversaries of February 6, 2024.
• New stock options totaling 14,499 were granted on February 18, 2026, with an exercise price of $129.13 per share, vesting in one-third increments on the first, second, and third anniversaries.
• Further stock options were reported with exercise prices of $156.64 (8,642 options), $196.14 (6,127 options), and $162.07 (6,542 options), each with one-third vesting on the first, second, and third anniversaries of their respective grant dates.
• Previously granted stock options totaling 20,221 were also listed, including 7,738 options granted February 11, 2020, at $144.03; 7,106 options granted February 10, 2021, at $160.62; and 5,377 options granted February 8, 2022, at $201.30.
• All equity awards were granted pursuant to the Zoetis Inc. Amended and Restated 2013 Equity and Incentive Plan, and stock options expire on the tenth anniversary of their grant date.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive disclosure, reflecting routine executive compensation that aligns management incentives with shareholder interests, without indicating any significant operational or financial changes for the company.

Positives

• Grants of Restricted Stock Units (RSUs) and Stock Options align executive interests with long-term shareholder value.
• The equity awards serve as a key component of executive compensation, incentivising continued service and performance.
• The multi-year vesting schedules for both RSUs and stock options promote executive retention over several years.

Future Outlook

The filing indicates future vesting of Restricted Stock Units and stock options on various anniversaries of their grant dates, extending through February 2026, contingent on the reporting person's continued service.

Industry Context

StockSavvy.ai notes that the grant of restricted stock units and stock options is a standard practice in executive compensation across various industries, including the animal health sector, designed to align executive incentives with long-term shareholder value and promote retention.

Comparison to Industry Standards

• The equity compensation structure, involving both restricted stock units and stock options with multi-year vesting schedules, is consistent with common practices observed in large-cap pharmaceutical and animal health companies such as Elanco Animal Health (ELAN) and IDEXX Laboratories (IDXX).
• These structures are designed to incentivize long-term performance and executive retention, aligning with global benchmarks for executive compensation.

Stakeholder Impact

• Shareholders: Potential positive impact through increased alignment of executive incentives with long-term company performance.
• Employees: No direct impact on general employees, but reinforces the company's executive compensation structure.

Next Steps

• Vesting of 3,664 Restricted Stock Units on the first, second, and third anniversaries of February 18, 2026.
• Vesting of 2,250.4257 Restricted Stock Units on the first, second, and third anniversaries of February 19, 2025.
• Vesting of 545 Restricted Stock Units on the first, second, and third anniversaries of February 6, 2024.
• Vesting of 14,499 stock options on the first, second, and third anniversaries of February 18, 2026.
• Vesting of 8,642 stock options on the first, second, and third anniversaries of February 19, 2025.
• Vesting of 6,127 stock options on the first, second, and third anniversaries of February 6, 2024.
• Expiration of stock options on the tenth anniversary of their respective grant dates.

Key Dates

Keywords

Zoetis Inc., ZTS, SEC Form 4, insider transaction, equity compensation, restricted stock units, stock options, executive compensation, beneficial ownership, corporate governance